FYI From Human Genome Sciences: GlaxoSmithKline Announces Positive Data From Harmony 8 Phase 3 Trial And Completion Of Clinical Registration Package For Albiglutide In Type 2 Diabetes

Attached is a press release issued earlier today by GlaxoSmithKline, announcing that data have been received from the Phase 3 Harmony 8 study and from the event-driven meta-analysis for assessment of cardiovascular safety conducted across the albiglutide clinical program in type 2 diabetes. These data are the final elements required to complete the clinical registration package.

Albiglutide, an investigational once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist, was created by HGS using its proprietary albumin-fusion technology, and was licensed to GSK in 2004. HGS is entitled to fees and milestone payments that could amount to as much as $183 million – including $33.0 million received to date – in addition to single-digit net royalties on worldwide sales if albiglutide is commercialized.

All inquiries regarding the albiglutide Phase 3 data announced today should be directed to the contacts provided by GSK.

Human Genome Sciences exists to place new therapies into the hands of those battling serious disease. For more information about HGS, please direct inquiries to the HGS contacts provided, or visit the Company’s web site at HGS and Human Genome Sciences are trademarks of Human Genome Sciences, Inc. Other trademarks referenced are the property of their respective owners.


This announcement includes statements that are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include those regarding our expectations for albiglutide, among others. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this announcement, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events or circumstances.

If you liked this article you might like

Stock Futures Waver as Earnings Season Begins

Stocks to Watch: WellPoint, Amerigroup, Alcoa (Update 1)

5 Things You Should Know Before the Stock Market Opens

Celgene Not Buying Human Genome Sciences

Human Genome Sciences Inc (HGSI): Today's Featured Health Care Winner